Clinical Trials

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05436327 2026-04-16

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

479 enrolled

Communication, Neoplasms

NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

21 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

402 enrolled

Neoplasms

NCT04905069 2026-04-15

SABRE

500 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT06502977 2026-04-15

DeLLphi-307

32 enrolled 9 charts

EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT00119912 2026-04-14

NORCCAP

100,000 enrolled

Gastrointestinal

Adenoma, Neoplasms, Colorectal Neoplasms

NCT01538550 2026-04-14

Pilot Study of a National Screening Programme for Bowel Cancer in Norway

140,000 enrolled

Gastrointestinal

Adenoma, Neoplasms, Colorectal Neoplasms

NCT03768336 2026-04-14

A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors

72 enrolled 8 charts

Neoplasms

NCT04958239 2026-04-14

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Neoplasms

NCT05611632 2026-04-14

NHS-Galleri

142,318 enrolled

Neoplasms

NCT05797246 2026-04-14

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

124 enrolled 17 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02864992 2026-04-13

VISION

337 enrolled 13 charts 4 FDA

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02908906 2026-04-13

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

413 enrolled

Neoplasms

NCT03148418 2026-04-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

382 enrolled

Neoplasms

NCT04606381 2026-04-13

PALOMA

158 enrolled

Neoplasms

NCT05155605 2026-04-13

PATHFINDER 2: A Multi-Cancer Early Detection Study

35,885 enrolled

Neoplasms

NCT06403436 2026-04-13

TT-CSP-001

50 enrolled

Disease, Neoplasms

NCT04847466 2026-04-08

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

18 enrolled

Neoplasms

NCT05462717 2026-04-08

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

GastrointestinalGynecologicThoracic

222 enrolled

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

87 enrolled

Neoplasms

NCT07263815 2026-04-08

EQUIP

25 enrolled

Disease, Neoplasms

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

33 enrolled

Lymphoid

Lymphoma, Follicular, Neoplasms

NCT07217145 2026-04-07

PREVENT HPV -Related Cancers Trial

1,455 enrolled

Behavior, Communication, Neoplasms, Patient Acceptance of Health Care, Papillomavirus Infections

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

LymphoidOther hematologic neoplasm

25 enrolled

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Neoplasms

NCT05629234 2026-04-06

ROSY-T

37 enrolled

Neoplasms

NCT05784766 2026-04-06

SARIC

494 enrolled

Neoplasms

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02584933 2026-04-02

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Phase 4 Active not recruiting

233 enrolled